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Abstract
Increased activity of the Src tyrosine protein kinase that has been observed in a large number of human malignan-
cies appears to be a promising target for drug therapy. In the present study, a critical role of the Src activity in the
deregulation of mTOR signaling pathway in Rous sarcoma virus (RSV)–transformed hamster fibroblasts, H19 cells,
was shown using these cells treated with the Src-specific inhibitor, SU6656, and clones of fibroblasts expressing
either the active Src or the dominant-negative Src kinase-dead mutant. Disruption of the Src kinase activity results
in substantial reduction of the phosphorylation and activity of the Akt/protein kinase B (PKB), phosphorylation of
tuberin (TSC2), mammalian target of rapamycin (mTOR), S6K1, ribosomal protein S6, and eukaryotic initiation fac-
tor 4E–binding protein 4E-BP1. The ectopic, active Akt1 that was expressed in Src-deficient cells significantly en-
hanced phosphorylation of TSC2 in these cells, but it failed to activate the inhibited components of the mTOR
pathway that are downstream of TSC2. The data indicate that the Src kinase activity is essential for the activity
of mTOR-dependent signaling pathway and suggest that mTOR targets may be controlled by Src independently of
Akt1/TSC2 cascade in cells expressing hyperactive Src protein. These observations might have an implication in
drug resistance to mTOR inhibitor–based cancer therapy in certain cell types.
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Introduction
Growth-regulating signals originating from within and outside the
cell are integrated through serine/threonine protein kinase mamma-
lian target of rapamycin (mTOR) that has a key role in many aspects
of cellular physiology. The mTOR signaling network has been impli-
cated in the regulation of many cell functions including transcrip-
tion, ribosome biogenesis, mRNA turnover, autophagy, cytoskeletal
organization, and translation of specific subsets of mRNAs. There are
several links between mTOR signaling and human diseases such as
cancer (reviewed in the study of Wullschleger et al. [1]).
mTOR exists in two heteromeric complexes, mTORC1 and
mTORC2. mTORC1 is the only known target of the specific in-
hibitor of mTOR, drug rapamycin. It consists of three proteins,
mTOR, mLST8, and regulatory-associated protein of TOR, and
the mTORC1-dependent pathway signals to the translational control
of protein synthesis. The mTORC2 complex has been shown to con-
tain mTOR, mLST8, and rapamycin-insensitive companion of
mTOR and to control actin cytoskeleton dynamics [2]. Recently,
protein PRAS40 that associates with 14-3-3 proteins has been iden-
tified as another target for regulation by mTORC1, but not by
mTORC2 [3,4].
mTORC1 regulates cap-dependent translation especially of mRNAs
with structured 5′-UTRs. It is facilitated by the phosphorylation and
inactivation of 4E-BPs that are the suppressors of the cap-binding pro-
tein eIF4E, which plays a central role in cap-dependent translation by
interacting with the 5′-cap structure of the mRNA. Many of these
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mRNAs encode proteins that control cell cycle progression and prolif-
eration. mTORC1-regulated phosphorylation of ribosomal protein S6
by p70 S6 kinase (S6K1) increases selective translation of mRNAs en-
coding critical protein components of the proteosynthetic apparatus
and cell size. Deregulation of the selective mRNA translation may play
an important role in carcinogenesis, has direct consequences on cancer
initiation, and can contribute to cell transformation (reviewed in the
study of Holland et al. [5]).
In cancer cells, some of the proteins shown upstream or down-
stream of mTOR may be deregulated. An important negative regu-
lator of mTOR is the suppressor protein tuberous sclerosis complex
(TSC1/2) comprising hamartin (TSC1) and tuberin (TSC2). TSC2
is a 198-kDa protein, which contains the GTPase activator domain
that promotes hydrolysis of GTP bound to the small GTPase Rheb
activating mTOR [6]. Phosphorylation of TSC2 inactivates the
GTPase activator domain function of TSC2, disrupts the TSC1/2
complex and stimulates activity of Rheb and mTOR [7]. The
TSC1/2 complex may receive inputs from diverse signaling path-
ways; many growth-regulated proteins interact with the TSC1/2
complex and thus regulate mTOR. However, regulation of mTOR
in a TSC1/2–independent fashion has also been reported [8].
TSC2 acts downstream of phosphatidylinositol 3–kinase (PI-3K)
and protein kinase B (Akt/PKB), being directly phosphorylated at
Ser939 and Thr1462 and thereby regulated by Akt/PKB [9].
TSC2 may also be phosphorylated by AMP-activated protein kinase
[10] and by RSK (p90 S6 kinase), the downstream effector of the
Ras/mitogen-activated protein kinase signaling pathway [11].
The serine/threonine kinase Akt/PKB, originally identified as an
oncogene, plays a key role in cell survival, growth, proliferation, an-
giogenesis, metabolism, and migration. The three Akt isoforms
(Akt1, Akt2, and Akt3) that may have distinct physiological func-
tions (reviewed in the study of Manning and Cantley [12]), comprise
an amino-terminal pleckstrin homology (PH) domain and a kinase
domain. A multistep mechanism of the activation of Akt/PKB has
been proposed, including interaction of the PH domain within
Akt/PKB with phosphatidylinositol triphosphates produced by PI-
3K and subsequent translocation of Akt/PKB to the plasma mem-
brane. Following membrane location, Akt/PKB can interact with
the tyrosine kinase Src [13]. The interaction between the SH3 do-
main of Src and a proline-rich motif (PXXP) in the C-terminus of
Akt/PKB may allow Src kinase to phosphorylate Akt/PKB at Tyr315
and Tyr326 [13,14] and probably also at Tyr474 [15]. Tyrosine phos-
phorylation was shown to be required for Akt/PKB phosphorylation at
Thr308 in the activation loop by phosphoinositide-dependent kinase 1
(PDK1) and subsequent full activation by the phosphorylation at
Ser473 within the carboxy-terminal tail catalyzed by other kinases,
not yet clearly identified. The mTORC2 complex has been recently
shown to mediate phosphorylation of Akt/PKB at Ser473 [16]. The
involvement of the mTORC2 complex was also observed in the feed-
back phosphorylation of Akt/PKB at Ser473 when treated with the
Akt/PKB inhibitor A-443654 [17].
Despite the great progress in the analyses of mTOR signaling,
some aspects of its function are still unclear and many new questions
have arisen, especially regarding the involvement of mTOR in the
regulatory positive and negative feedback mechanisms. Treatment
with rapamycin inhibits proliferation and may lead to apoptosis,
and thus rapamycin and its analogs are evaluated in clinical trials
as important anticancer agents. Although rapamycin is a selective in-
hibitor of mTOR and its downstream signaling, the inhibition of
mTOR by rapamycin was shown in a subset of human cancer cell
lines also to induce Akt/PKB phosphorylation at Ser473 mediated
through receptor tyrosine kinase activation [18] or PI-3K–dependent
phosphorylation of Akt/PKB and eIF4E [19]. These events seem to
attenuate growth-inhibitory effects of rapamycin and serve as a neg-
ative feedback mechanism that could induce drug resistance.
Conversely, prolonged rapamycin treatment inhibits Akt/PKB sig-
naling through suppression of mTORC2 assembly [20] and tumors
expressing activated Akt/PKB that are resistant to conventional che-
motherapy agents could be sensitized to chemotherapy-induced
death by rapamycin [21]. Currently, it seems rather difficult to define
a role of mTOR, particularly in the positive and negative feedback
regulatory mechanisms.
We have previously shown that a model cell line (Rous sarcoma
virus (RSV)–transformed hamster fibroblasts, H19 cells) expressing
hyperactive Src protein displayed enhanced protein synthesis and up-
regulated PI-3K/Akt and mTOR-dependent signaling [22]. Signifi-
cant changes in these pathways suggested that Akt/PKB was not
an upstream effector of the mTORC1 targets, S6K1 and 4E-BP1,
in RSV-transformed cells. In the present study, we examined a role
of the active, ectopic Akt1 expressed in hamster fibroblasts in which
the activity of the Src kinase was suppressed. Using the pharmacolog-
ical inhibitor of the Src kinase activity, SU6656, and a dominant-
negative kinase-dead double Y416F–K295N mutant of Src [23] to
disrupt the Src enzymatic activity, we observed that inhibition of
the protein kinase activity of Src blocked the mTORC1 signaling
and that this block could not be overridden by the constitutively ac-
tive form of Akt1. It may imply that mTORC1 downstream signal-
ing is controlled by the Src kinase activity independently of Akt/PKB
in RSV-transformed cells.
Materials and Methods
All general reagents were from Sigma (St. Louis, MO) unless oth-
erwise stated. Protein G-Sepharose and [γ-32P]ATP were obtained
from GE Healthcare Bio-Sciences (Uppsala, Sweden). Anti–phospho-
Akt(Tyr326), anti–phospho-Akt(Thr308), anti–phospho-Akt(Ser473),
anti–phospho-mTOR(Ser2448), anti–phospho-S6(Ser235/236),
anti–phospho-tuberin(Thr1462), anti-S6K1, anti-S6, anti–4E-
BP1, anti-tuberin, and anti-Akt antibodies were purchased from Cell
Signaling Technology (Danvers, MA), and anti–haemaglutinin
(HA)-tag antibody was from Santa Cruz Biotechnologies (Santa Cruz,
CA). The anti-Src antibody LA074 and the anti-tubulin antibodywere as
in the study of Vojtěchová et al. [23]. The inhibitor SU6656 was ob-
tained from Biomol International (Exeter, UK). Recombinant protein
Akt and the active recombinant glutathione S-transferase (GST)–Src fu-
sion protein were from Upstate Biotechnologies (Charlottesville, VA).
Cell Culture and Preparation of Cell Extracts
RSV-transformed hamster fibroblasts H19, nontransformed ham-
ster fibroblasts NIL-2, NIL-A cells expressing the active wild-type v-
Src, and NIL-B cells expressing the kinase-dead double mutant v-Src
were grown in the presence of 5% fetal calf serum as described [23].
Cells were brought to quiescence by an overnight incubation with
2% fetal calf serum and then treated with the inhibitor SU6656 or
rapamycin added to a final concentration of 5 μM and 20 nM
(DMSO solution diluted in a medium, 1:106), respectively, or
DMSO carrier alone for 30 minutes. The cells were lysed in an
ice-cold extraction buffer [40 mM β-glycerophosphate, 50 mM
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HEPES pH 7.4, 5 mM EGTA, 1 mM Na3VO4, 1 mM benzamidine,
3 mM Na4P2O7, 0.5 mM PMSF, 1% Triton X-100, and the protein-
ase inhibitors pepstatin, antipain, and leupeptin (0.4 μg/ml each)]
unless otherwise indicated. Cell debris was pelleted by centrifuging
at 20,000g for 10 minutes, and supernatants were assayed for pro-
tein concentration.
Immunoprecipitation of Proteins, Western Blot Analysis,
and Purification of S6 Protein
Proteins were immunoprecipitated from the cell extracts on Pro-
tein G-Sepharose beads, and the resulting immunoprecipitates were
used either for SDS-PAGE followed by immunoblot analysis or for
the in vitro kinase assays as described previously [22]. The S6 ribosomal
protein was purified from the nontransformed NIL-2 cells by SP-
Sepharose column chromatography and HPLC on a C18 column [24].
Soft Agar Assay
The assay was carried out in 60-mm Petri dishes. Approximately 5 ×
103 cells were seeded in the upper layer containing 3 ml of modified
Eagle’s medium, 0.3% agar, 5% FCS supplemented with DMSO or
inhibitors in a final concentration of 5 μM SU6656 or 20 nM rapa-
mycin. The cell media were refreshed every 3 to 4 days. The colonies
were stained with p-indonitrotetrazolium violet (#18377; Sigma),
counted, and photographed (magnification, × 20) after 12 days.
Protein Kinase Assays
Src activity. The reaction was carried out in 25 μl of a mixture
containing 50 mM Tris–HCl pH 7.5, 10 mM MgCl2 or 10 mM
MnCl2, 50 μM Na3VO4, 5 mM DTT, 50 μM ATP, 1 μCi [γ-
32P]
ATP, 1 μg of denatured enolase, and Src protein immunoprecipitated
from analyzed cells, and was incubated for 25 minutes at 30°C.
The samples were subjected to SDS-PAGE/immunoblot analysis
and autoradiography.
S6K1 activity. The assay was carried out in 25 μl of a mixture con-
taining 50 mM Tris–HCl pH 7.5, 10 mM MgCl2, 40 μM Na3VO4,
5 mM DTT, 0.25 μl of PKA inhibitor substrate, 50 μM ATP, 6 μCi
[γ-32P]ATP, and 2 μg of purified S6 protein. The samples were sub-
jected to SDS-PAGE/immunoblot analysis and autoradiography.
Akt/PKB activity. The kinase activities in either anti-Akt or anti–
HA-tag immunoprecipitates were assayed with RPRAATF peptide as
described previously [22]. To analyze ectopic iAkt and endogenous
Akt/PKB separately, the iAkt was precipitated with the anti-HA an-
tibody, and the endogenous Akt/PKB was then immunoprecipitated
from the resulting supernatants with anti-Akt antibody.
Construction and Use of an Inducible Akt Adenovirus
We used a recombinant adenovirus expressing the estrogen-dependent,
constitutively active form of human Akt/PKB. This construct was
derived from the human Akt-1 by replacing the PH domain with
the N-terminal myristoylation signal and fusing the mutant murine
anti–estrogen receptor modified for tamoxifen to its C-terminus. On
infection of the cells, the Akt1 protein is expressed, but its full enzy-
matic activity requires induction by 4-hydroxytamoxifen (HT) [25].
Infections of the Cells with an Inducible Akt Adenovirus
The cells were coinfected with equal amounts of two recombinant
adenoviruses, one encoding a tetracycline-inhibited transactivator,
and the other a tetracycline-inhibited transactivator–regulated gene
expressing HT-inducible HA-tagged membrane-targeted Akt1 as de-
scribed [26]. After infection, cells were grown until their confluence
and then incubated overnight in F10/DMEM with 1% FCS in the
absence or presence of 1 μM HT. The next day, cells were treated
either with a vehicle (DMSO) or with 5 μM SU6656 or 20 nM ra-
pamycin for 30 minutes and extracted as described above.
Src Kinase Mutants
The active v-Src kinase and the Src kinase-dead double Y416F–
K295N mutant were prepared as reported [23]. The active, wild-type
H19 v-src gene or the kinase-dead double Y416F–K295N v-src mu-
tant were stably transfected in the embryonic hamster fibroblasts
NIL-2. The cells were cloned and two cell lines were established,
namely, the NIL-A cells expressing the active v-Src protein and the
NIL-B cells expressing the Src kinase-dead protein.
Results
The Inhibitor of Src Tyrosine Kinase Activity, SU6656,
Suppresses Akt/PKB and mTOR Signaling in H19 Cells
It has been recently reported that tyrosine kinase inhibitors PP1
and PP2 inhibited protein translation through implication of tyrosine
phosphorylation in the cap-dependent translation [27]. The inhibi-
tion of serine/threonine phosphorylation and the activity of S6K1,
Akt/PKB, and ERK1/2 by inhibitors PP1 and PP2 was also reported
[27,28], and it was suggested that Src kinase activity may be involved
in the regulation of the PI-3K/mTOR signaling pathway. This path-
way was shown to be highly upregulated in RSV-transformed ham-
ster fibroblasts (H19 cells) expressing hyperactive Src protein
[22,29]. To analyze the involvement of the Src kinase activity in
the regulation of the mTOR-dependent signaling in H19 cells in
more detail, we treated these cells with a specific inhibitor of the
Src family kinase, SU6656 [30].
The inhibitory efficiency of SU6656 is demonstrated by a reduced
phosphorylation of Src at its catalytic Tyr416 in RSV-transformed
fibroblasts treated with SU6656 (Figure 1A) and by a decreased ac-
tivity of Src immunoprecipitated from the inhibited H19 cells in the
in vitro kinase assay (Figure 1B). Akt/PKB was also upregulated in
cells transformed by the v-src oncogene [22], and Src has been sug-
gested to act as a putative priming kinase for Akt/PKB [14]. In agree-
ment with this hypothesis, the decreased activity of Src correlated
well with a decreased phosphorylation of Akt/PKB at Tyr326 and
also at Ser473 and Thr308 residues, when treating the H19 cells
with SU6656 (Figure 1C ). Phosphorylation of recombinant Akt/
PKB by the active GST–Src fusion protein showed that Akt/PKB
is indeed directly phosphorylated by Src in vitro (Figure 1D).
Treatment of H19 cells with SU6656 also resulted in a decreased
phosphorylation level of mTOR at Ser2448, presumably phosphor-
ylated by Akt/PKB or by S6K1 in feedback mechanism [31,32], and
in reduced phosphorylation of the downstream targets of mTOR,
S6K1 and 4E-BP1, as manifested by higher electrophoretic mo-
bility of these proteins on SDS-PA gels (Figure 2A). Decreased phos-
phorylation of S6K1 is accompanied by a substantial reduction of
the S6K1 activity as judged by the dephosphorylation degree of its
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physiological substrate, ribosomal protein S6 in vivo (Figure 2A), and
the decreased in vitro phosphorylation of the purified ribosomal S6
protein catalyzed by S6K1 that was immunoprecipitated from H19
cells treated with SU6656 (Figure 2B). These data imply that the
deregulation of mTORC1 signaling may critically depend on the
Src tyrosine kinase activity in RSV-transformed cells.
Suppressed Phosphorylation of TSC2 But Not of mTORC1
Downstream Targets Was Restored By the Active, Ectopic
Akt Expressed in Src-Inhibited H19 Cells
Although Akt/PKB was shown to be an upstream regulator of
mTOR signaling in many cell types, we have found previously [22]
(and unpublished results) that, when treating the RSV-transformed cells
with the selective inhibitors of PI-3K wortmannin and LY294002, the
phosphorylation and activity of Akt/PKB decreased, but it was not ac-
companied by the inhibition of mTOR and its targets S6K1 and
4E-BP1. It might indicate that Akt/PKB is not involved in mTORC1
downstream signaling in H19 cells. Therefore, we examined the possi-
bility that suppression of mTOR signaling by the inhibition of the Src
activity could be overcome by ectopic, constitutively active Akt.
A recombinant adenovirus encoding HT-inducible HA-tagged
membrane-targeted Akt1 (iAkt) was used as described in the Materials
and Methods section. This ectopic, myristoylated PH domain-deleted
Akt1 is PI-3K–independent, does not require phosphatidylinositol tri-
phosphates, PI-3K products, for its activity, and was not inhibited
by LY294002 [26]. In the infected cells, the iAkt protein is expressed,
but its full enzymatic activity requires presence of HT [25] as demon-
strated in Figure 3A. In the presence of HT, ectopic iAkt was phos-
phorylated at Ser473 and Thr308 (Figure 3A, lanes 3 and 4 ), and
unexpectedly, unlike in endogenous Akt/PKB, this phosphorylation
was not changed when treating the cells with the Src inhibitor
SU6656 (Figure 3A, lanes 4 and 5). Phosphorylation of Ser473 and
Thr308 residues of endogenous Akt/PKB significantly decreased in
both uninfected and infected cells H19 when treating with SU6656
(Figure 3A, lanes 1 and 2 and lanes 4 and 5, respectively), suggesting
Figure 1. Inhibition of Src activity by SU6656 results in the reduced phosphorylation of Akt/PKB in H19 cells. (A) Phosphorylation of Src
at Tyr416 residue. Crude extracts of H19 cells that were treated with either SU6656 (5 μM) or the vehicle (DMSO) were analyzed by SDS-
PAGE followed by immunoblot analysis using anti–phospho-Src(Tyr416) and anti-Src antibodies. (B) In vitro kinase activity of Src. Auto-
radiography of SDS-PAGE of the reaction mixtures containing Src immunoprecipitated from H19 cells treated with 5 μM SU6656 or with
the vehicle (DMSO) that were incubated in the presence of [γ-32P]ATP and enolase (1 μg) as described in the Materials and Methods
section. (C) Effect of the Src-specific inhibitor SU6656 on the phosphorylation of Akt at Tyr326, Ser473, and Thr308 residues. Crude
extracts of H19 cells treated with SU6656 (5 μM) or with the vehicle (DMSO) were analyzed by SDS-PAGE followed by immunoblot
analysis using anti–phospho-Akt(Tyr326), anti–phospho-Akt(Thr308), anti–phospho-Akt(Ser473), and anti-Akt antibodies. (D) In vitro phos-
phorylation of Akt/PKB catalyzed by Src. Autoradiography of SDS-PAGE of the reaction mixtures containing recombinant protein Akt/PKB
with (1) or without active recombinant GST–Src fusion protein (2) that were incubated in the presence of [γ-32P]ATP as described in the
Materials and Methods section.
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that whereas the endogenous Akt/PKB is a target of the Src kinase
activity, the ectopic iAkt is not regulated by Src in H19 cells.
In agreement with this observation, the ectopic iAkt was not phos-
phorylated at Tyr326 in H19 cells either in the absence or presence
of HT (Figure 3A, lanes 3–5). The lack of tyrosine phosphorylation
in iAkt was confirmed by immunoblot analysis using a general anti-
phosphotyrosine antibody (not shown). It indicates that this mutant
form of Akt can be phosphorylated at Ser473 and Thr308, irrespec-
tive of its tyrosine phosphorylation status. Moreover, this ectopic
iAkt displayed a very high enzymatic activity as measured by in vitro
phosphorylation of the substrate peptide RPRAATF catalyzed by the
ectopic iAkt immunoprecipitated by anti–HA-tag antibody from the
analyzed cells (Figure 3B).
Dephosphorylation of TSC2 at Thr1462, which is a phosphory-
lation site for Akt/PKB [9], is in agreement with the fact that Akt/
PKB was inhibited in H19 cells treated with SU6656. Because TSC2
is the upstream negative regulator of mTOR, suppression of its phos-
phorylation and thus activation could be a reason of attenuation of
the mTOR pathway activity mediated by Src inhibition (Figure 3C,
lanes 1 and 2). We tested whether expression of the active iAkt could
restore inhibited phosphorylation of TSC2 and the mTOR signaling
pathway. As shown by immunoblot analysis, an increased level of
phosphotuberin appeared in H19 cells infected with constitutively
active iAkt compared to the cells containing only endogenous Akt/
PKB (Figure 3C, lanes 3–5). Conversely, the expression of iAkt did
not overcome the inhibition of components of the mTOR signaling
pathway by SU6656 that are downstream to tuberin. As demonstrated
in Figure 4 (lanes 1 and 2 and lanes 5 and 6, respectively), infection of
H19 cells with iAkt had no effect on the decreased phosphorylation of
S6K1, ribosomal protein S6 and 4E-BP1 induced by SU6656 treat-
ment in H19 cells (Figure 4, lanes 2 and 6 ).
To compare the efficiency of SU6656-mediated suppression of
mTOR signaling with the inhibition of mTOR signaling pathway
by the mTOR-specific inhibitor rapamycin, we examined the effect
of rapamycin in H19 cells uninfected or infected with the ectopic iAkt.
Although the inhibition of mTOR by rapamycin may induce activa-
tion of endogenous Akt/PKB in a regulatory negative feedback [17–
20], no effect of rapamycin treatment on the phosphorylation of en-
dogenous or ectopic Akt was observed in the H19 cells (not shown).
SU6656 showed to be rather less effective than rapamycin. On
treatment with SU6656, the phosphorylation of S6K1, ribosomal
protein S6, and 4E-BP1 decreased, but not to that induced by rapa-
mycin (Figure 4, lanes 1–3). The activity of S6K1 was also less in-
hibited by SU6656 than by rapamycin, as indicated by the degree of
dephosphorylation of the ribosomal S6 protein in treated H19 cells
(Figure 4, lanes 2 and 3). Infection of H19 cells with ectopic, active
iAkt failed to overcome the inhibitory effects of rapamycin as well
(Figure 4, lanes 3 and 7 ).
Thus, in H19 cells, the overexpression of the ectopic, active iAkt
does not restore the phosphorylation of S6K1, ribosomal protein S6,
and 4E-BP1 that was suppressed when treating the cells with rapamy-
cin or SU6656. Nevertheless, iAkt enhanced the phosphorylation of
TSC2 suppressed on Src inhibition, which may imply that the Src ac-
tivity affects the mTOR downstream targets independently of TSC2.
Dominant Negative Src Inhibits Both Akt/PKB
and mTOR Signaling
In addition to the pharmacological inhibition of the Src kinase activ-
ity by SU6656, we analyzed the cells in which the Src kinase activity was
suppressed by mutations in the kinase domain of the active Src protein,
as described in the Materials and Methods section. Expression of the
kinase-dead double Src mutant Y416F–K295N in NIL-B cells de-
creased Tyr416 phosphorylation of the total Src protein present in these
cells (Figure 5A, upper panel ), in agreement with a dominant negative
effect of this Src mutant on the endogenous c-Src in hamster fibroblasts
shown previously [23]. The presence of inactive Src in NIL-B cells ab-
rogated the phosphorylation of endogenous Akt/PKB at Tyr326, con-
firming that this residue is indeed the Src target (Figure 5A).
Infection of NIL-A cells (expressing wild-type v-Src) and NIL-B
cells (expressing kinase-dead Src) with the ectopic, active iAkt showed
that iAkt was not phosphorylated at Tyr326 in these cells, similarly as
in H19 cells. No decrease in the phosphorylation of Ser473 and
Thr308 residues was observed in the ectopic iAkt in NIL-B cells,
whereas phosphorylation of these residues in the endogenous Akt/
PKB was significantly reduced in NIL-B cells compared to NIL-A cells
Figure 2. Src kinase inhibitor SU6656 suppresses mTOR signaling.
(A) Crude extracts of H19 cells nontreated (DMSO) or treated with
SU6656 (5 μM) were subjected to immunoblot analysis using anti–
phospho-mTOR(Ser2448), anti–S6K1, anti–phospho-S6(Ser235/
236), anti-S6, anti–4E-BP1, and anti-tubulin antibodies. The phos-
phorylation status of S6K1 and 4E-BP1 was determined by means
of their migration on SDS-PAGE. The least phosphorylated form of
S6K1 or 4E-BP1 is represented by the most rapidly migrating pro-
tein band α [29]. Under these conditions, the total amount of S6
protein was not affected. Tubulin was used as a loading control.
(B) In vitro phosphorylation of S6 protein purified from normal fi-
broblasts catalyzed by S6K1. Autoradiography of SDS-PAGE of the
reaction mixtures containing S6K1 immunoprecipitated from H19
cells treated with SU6656 (5 μM) or with the vehicle (DMSO) that
were incubated in the presence of [γ-32P]ATP and purified S6 pro-
tein (1 μg) as described in the Materials and Methods section.
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(Figure 5A). This correlates well with the decreased phosphorylation of
endogenous Akt/PKB at Ser473 and Thr308 observed in H19 cells
when treated with SU6656 as shown in Figure 1C.
Phosphorylation of TSC2 was reduced in the Src-deficient NIL-B
cells and increased in both NIL-A and NIL-B cells that were infected
with the active iAkt compared to the uninfected cells containing only
endogenous Akt/PKB (Figure 5B). Conversely, the expression of con-
stitutively active iAkt did not increase reduced phosphorylation of
S6K1 in NIL-B cells as measured by the electrophoretic mobility
of S6K1 on SDS-PA gels and by the phosphorylation of S6K1 at
Thr389. In addition, decreased phosphorylation of ribosomal protein
S6 in the Src-deficient NIL-B cells was not overcome by the expres-
sion of constitutively active iAkt (Figure 5B), similarly as observed in
H19 cells when treated with SU6656 (Figure 4).
The data obtained by the pharmacological inhibition of the Src
kinase activity by SU6656 in RSV-transformed hamster fibroblasts
appeared to correlate well with the data observed in the analyses of
hamster fibroblasts in which the total Src activity was suppressed by
the expression of the inactive Src protein. The results confirmed that
the Src tyrosine kinase activity plays an important role in mTORC1
signaling that is TSC2-independent in v-src–transformed cells.
Rapamycin and SU6656 Blocked the Soft Agar Colony
Formation of RSV-Transformed Cells
Because the Src-specific inhibitor SU6656, similarly as the mTOR-
specific inhibitor rapamycin, effectively downregulated mTORC1-
Figure 3. Effect of ectopic, active iAkt on the phosphorylation of endogenous Akt/PKB and tuberin reduced by SU6656 in H19 cells. (A)
Crude extracts of H19 cells uninfected or infected with ectopic, constitutively active iAkt as indicated were treated with SU6656 (5 μM)
or with the vehicle (DMSO) and analyzed by SDS-PAGE followed by immunoblot analysis using anti–phospho-Akt(Tyr326), anti–phospho-
Akt(Ser473), anti–phospho-Akt(Thr308), and anti-Akt antibodies. (B) In vitro kinase activity of Akt was assayed as described [22] using the
RPRAATF peptide (150 μg) as a substrate in the reaction mixtures containing iAkt expressed and immunoprecipitated from the infected
H19 cells by anti-HA antibody and the endogenous Akt/PKB immunoprecipitated from H19 cells either treated with the vehicle (DMSO)
or with SU6656 (5 μM) as indicated. Data are means ± SD of triplicate determination of three separate experiments. Mixtures containing
no peptide substrate were subtracted from the results. (C) Crude extracts of H19 cells uninfected or infected with ectopic iAkt as indi-
cated were treated with SU6656 (5 μM) or vehicle (DMSO), and analyzed by SDS-PAGE followed by immunoblot analysis using anti–
phospho-tuberin(Thr1462) and anti-tuberin antibodies.
Figure 4. Effect of the ectopic, active iAkt on the phosphorylation
of S6K1, ribosomal protein S6, and 4E-BP1 inhibited by SU6656
or rapamycin treatment in H19 cells. Crude extracts of H19 cells
uninfected or infected with ectopic iAkt were treated with the ve-
hicle (DMSO) or with either SU6656 (5 μM) or rapamycin (20 nM)
and analyzed by SDS-PAGE followed by immunoblot analysis
using anti-S6K1, anti–phospho-S6(Ser235/236), anti-S6, and anti–
4E-BP1 antibodies.
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dependent signaling to translational control of gene expression in H19
cells (Figure 4), we performed the soft agar colony formation assay to
examine their capability to influence the phenotype of RSV-transformed
hamster fibroblasts. As shown in Figure 6, both SU6656 and rapamycin
blocked the oncogenic transformation of H19 cells. Rapamycin was less
efficient than SU6656, and the number of colonies did not change when
both inhibitors were applied simultaneously. Anchorage-independent
growth induced by the v-src oncogene thus correlates with the activa-
tion of mTORC1-dependent signaling in H19 cells, suggesting that
mTOR is an important mediator of the oncogenic signals issued by
the v-src oncogene.
Taken together, the results obtained with the Src-specific inhibitor
SU6656 and the dominant negative mutant form of the Src protein
showed that the inhibition of the Src activity may suppress the activ-
ity of mTORC1-dependent signaling pathway. Furthermore, the data
indicate that the suppressive mechanism is not dependent on en-
dogenous Akt/PKB, which is also inhibited by the disruption of
the Src activity.
Discussion
The results presented in this study suggest a direct control of
Akt/PKB and mTORC1 signaling by the Src kinase activity in
RSV-transformed fibroblasts (H19 cells). The phosphorylation and
activity of Akt/PKB and the phosphorylation of tuberin (TSC2),
mTOR, S6K1, S6 protein, and 4E-BP1 decreased when the Src ki-
nase activity was disrupted both by treatment with the Src inhibitor
SU6656 or by the expression of Src kinase-dead double Y416F–
K295N mutant that has a dominant negative effect on the endogenous
c-Src [23]. The inhibition of downstream components of the mTOR-
dependent signaling pathway, S6K1 and 4E-BP1, was not overcome
by the expression of ectopic iAkt in H19 cells. These data suggesting
that Akt/PKB does not control the mTORC1 targets in these cells
are thus in agreement with our previous results demonstrating the
Figure 5. Dominant-negative Src inhibits phosphorylation and activity of endogenous Akt/PKB and S6K1. Crude extracts of cells NIL-A
and NIL-B either uninfected or infected with ectopic iAkt as described in the Materials and Methods section were analyzed by SDS-PAGE
followed by immunoblot analysis using: (A) anti–phospho-Src(Tyr416), anti-Akt, anti–phospho-Akt(Tyr326), anti–phospho-Akt(Ser473), and
anti–phospho-Akt(Thr308) antibodies; (B) anti-tuberin, anti–phospho-tuberin(Thr1462), anti-S6K1, anti–phospho-S6K1(Thr389), anti–phospho-S6
(Ser235/236), anti-S6 antibodies.
Figure 6. Rapamycin and SU6656 inhibit colony formation of RSV-
transformed cells in soft agar. The assay was carried out in 60-mm
Petri dishes as described in the Materials and Methods section.
The number of viable colonies was checked after 12 days of incu-
bation by staining with p-indonitrotetrazolium violet. Plotted re-
sults are the mean of two independent experiments.
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inhibition of Akt/PKB but not inhibition of S6K1 and 4E-BP1 when
treating the H19 cells with the PI-3K inhibitors wortmannin and
LY294002 [22] (and unpublished results).
However, decreased phosphorylation of tuberin, which is the Akt/
PKB substrate upstream of mTOR, was restored by the active, ec-
topic iAkt in Src-deficient cells, as shown in this study. Increased
phosphorylation of TSC2 by iAkt was therefore insufficient to over-
come the suppression of mTORC1 signaling induced by the inhibi-
tion of the Src activity.
It has been already reported that regulation of the mTOR pathway
may involve mechanisms that operate independently of TSC2 in cer-
tain types of mammalian cells [8]. Regulation of mTOR signaling by
the Src activity may be such additional input implicated in the con-
trol of mTOR-dependent pathway in RSV-transformed hamster fi-
broblasts. Interestingly, Src has been recently shown to bind and
directly phosphorylate the mTOR target, S6K1 [33].
Preclinical and clinical data strongly support the potent effect of
tyrosine kinase inhibitors as successful anticancer drugs. Similarly, as
the inhibitor of the Src tyrosine kinase activity, SU6656, induced in-
hibition of the serine/threonine phosphorylation of signaling proteins
of Akt/TSC2 and mTOR pathways demonstrated here, SU6656
treatment of NIH3T3 cells expressing the ETV6–NTRK3 onco-
protein attenuated the activation of Ras–ERK1/2 and PI-3K/Akt cas-
cades [34]. Tyrosine kinase inhibitor Tyrphostin (AG1024), which
inhibits cell proliferation and delays tumor growth in vivo, also inhib-
its phosphorylation of Akt/PKB besides tyrosine phosphorylation of
the Bcr–Abl oncoprotein [35]. The inhibition of the serine/threonine
phosphorylation and the activity of eIF4E, S6K1, Akt/PKB, and
ERK1/2 by tyrosine kinase inhibitors has also been reported [27,28].
Inhibition of the mTORC1 signaling by rapamycin has a cytostatic
or cytotoxic effect on cancer cells and was shown to restore the suscep-
tibility of certain resistant cancer cells to chemotherapy [21,36]. Treat-
ment with rapamycin, however, also induced activation of endogenous
Akt/PKB in several cancer cell lines [18,19], probably in a negative
feedback mechanism that may contribute to drug resistance.
Complementary inhibition by dual inhibitors that targeted Bcr–Abl
and Src were shown to be active in case of resistance to the inhibitor of
Bcr–Abl, imatinib, used alone in the therapy of chronic myelogenous
leukemia [37]. Similarly, the Src kinase inhibitors may be promising
agents, probably for dual drug treatment with other inhibitors of
mTOR signaling. Therapeutical efficiency might therefore be achieved
in human tumors, in which Akt/PKB and/or the mTOR signaling
pathway are activated in the regulatory positive or negative feedback
mechanism, by suppressing the kinase activity of Src. The fact that
nutritional deprivation [38], hypoxia [39], and inhibition of the Src
activity (this article) all reduce mTOR signaling indicates that mTOR
may function in hypoxic areas of tumors and in tumors with high Src
activity. The Src-dependent activation of the mTORC1 signaling to
translational control may promote enhanced selective expression of
proteins involved in certain malignant processes.
Our data show that besides rapamycin and its analogs, the specific
inhibitors of the mTOR signaling pathway currently examined as po-
tent antitumor agents, inhibitors of the Src activity may also display
a profound inhibition of mTOR signaling in some type of cells, in-
dependently of the activated Akt1. It is possible that Akt1 and Akt2,
which are expressed ubiquitously [12], may be redundant in the stud-
ied cells, and thus an isoform-specific substrate recognition might ex-
plain the Akt/PKB–independent regulation of S6K1 and 4E-BP1 in
RSV-transformed cells. Also, akt mutation [40] cannot be excluded.
However, the fact that the activity of TSC2, a substrate of the endog-
enous Akt/PKB of hamster fibroblasts, was regulated by the trans-
duced ectopic Akt1, whereas the activity of mTOR targets was not,
indicates that Akt1 is not able to overcome the suppression of
mTOR-dependent pathway induced by Src in these cells.
In conclusion, these data suggest that the activity of Src may have
an essential role in the Akt1/TSC2–independent regulation of the
mTORC1 signaling pathway in RSV-transformed hamster fibroblasts.
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